3Ross DD,Gao Y,Yang W,et al.The 95-kilodalton membrane glycoprotein overexpressed in novel multidrug-resistant breast cancer cells is NCA,the nonspecific cross-reacting antigen of carainoem bryonic antigen[J] .Cancer Res,1997,57(24):5460-5464.
4Mullner S,Neumann T, Lottspeich F. Proteomics a new way for drug target discovery[J]. Arzneim It Telforschung,1998,48(1):93-95.
5Kahn P. From genome to proteome:looking at a cell`s proteins[J].Science,1995,270:369-370.
6Steiner S, Aicher L, Raymackers J, et al. Decrese in kidiney calbindin D 28 kDa as a possible mechanism mediating cyclosporine A[J]. Biochem Pharmacol,1997,53:723-731.
7Dean PM, Zanders ED, Bailey DS. Industrial-scale,genomics based drug design and discovery[J].Trends Biotechnol,2001,19:288-292.
8Wasinger VC, Cordwell SJ, Cerpa-Poljak C, et al. Progress with geneproduct mapping of the mollic utes: Mycoplasma genitalium[J]. Electrophoresis,1995,16 (7) :1090.
9Serive RF. Structural genomics offers high-speed look at proteins[J].Science,2000,287:1954-1956.
10Caron PR, Mullican RD, Mashal RD, et al,Chemogenomic approaches to drug discovery[J].Curr Opin Biol,2001,5:464-470.
二级参考文献74
1[1]Caron PR, Mullican MD, Mashal RD, et al. Chemogenomic approaches to drug discovery. Curr Opin Chem Biol, 2001, 5:464～470.
2[2]Dean PM, Zanders ED, Bailey DS. Industrial-scale, genomics-based drug design and discovery. Trends Biotechnol, 2001,19:288～292.
3[3]Peet NP,Bey P.Pharmacogenomics:challenges and opportunities.DDT,2001,6:495～498.
4[4]Christendat D,Yee A,Dharamsi A,et al.Structural proteomics of an archaeon.Nat Struct Biol,2000,7:903～909.
5[5]Pandey A, Mann M. Proteomics to study genes and genomes. Nature, 2000, 405: 837～846.
6[6]Fields S. PROTEOMICS: Proteomics in Genomeland. Science, 2001,291: 1221～1224.
7[7]Lopez MF. Proteome analysis I. Gene products are where the biological action is. J Chromatography B, 1999, 722 :191～202.
8[8]Xhou W, Merrick BA, Khaledi MG, et al. Detection and sequencing of phosphopeptides affinity bound to immobilized metal ion beads by matrix-assisted laser desorption/ionization mass spectrometry. J Am Soc Mass Spectrom, 2000,11:273～282.
9[9]Srikrishna G, Wang L, Freeze HH. Fucosebeta-1-P-Ser is a new type of glycosylation: using antibodies to identify a novel structure in Dictyostelium discoideum and study multiple types of fucosylation during growth and development. Glycobiol, 1998,8:799～811.
10[10]Martzen MR,McCraith SM,Spinelli SL,et al.A biochemical genomics approach for identifying genes by the activity of their products.Science,1999,286:1153～1155.
5Wasinger VC, Cordwell SJ, Cerpa-Poljak A, el al. Progress with gene-produet mapping of the mollieutes:myeoplasma genitalium[J].Eleetrophoresis, 1995, 16(7): 1090.
6Cho C, NuttaU ME. Emerging techniques for the discovery and validation of therapeutic targets for skeletal diseases [J]. Expert Opin Ther Targets, 2002,2(6): 679.
7Hanash SM, Madoz Gurpide, J Misek DE. Identification of novel targets for cancer therapy using expression proteom ics [J].Leukemia, 2002,16(4): 478.
8Betts JC. Transcfiptom ies and proteom ies tools for the identification of novel drug targets and vaccine candidates for tuberculosis [J]. IUBMB Life, 2002, 53(4-5): 239.
9Tang H, Peng T, Wong Staal F. Novel technologies for studying virushost interaction and discovering new drug targets for HCV and HIV [J]. Curr Opin Phamacol,2002, 2(5): 541.
10Coombes BK, Johnson DI, Mahony JB. Strategic targeting of essential host-pathogen interactions in chlamydial disease [J]. Curr. Drug Targets Infect Disord, 2002,2(3): 201.
